Profile: Amarin Corporation PLC (AMRN.OQ)
Amarin Corporation plc, incorporated on March 1, 1989, is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
The Company has an agreement with Eddingpharm (Asia) Macao Commercial Offshore Limited (Eddingpharm), to develop and commercialize Vascepa capsules in Mainland China, Hong Kong, Macau and Taiwan, or the China Territory. The Company also has an agreement with Biologix FZCo to register and commercialize Vascepa in countries within the Middle East and North Africa. It is also assessing other partnership opportunities for licensing Vascepa to partners outside of the United States. In the Phase III MARINE and ANCHOR clinical trials, Vascepa is studied at a daily dose of two grams and four grams. The Company uses third-party manufacturers and suppliers to manufacture clinical and commercial active pharmaceutical ingredient (API) within Vascepa, and to encapsulate and package Vascepa. The API material that constitutes ethyl- eicosapentaenoic acid (EPA) is a modified, naturally occurring substance, which is sourced from qualified producers of specific fish oils.
The Company competes with GlaxoSmithKline plc, AbbVie, Inc., Teva Pharmaceuticals USA Inc., Par Pharmaceutical Inc., Apotex Inc., AvKare Inc., Amneal Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Golden State Medical Supply and Prasco Labs.
Amarin Corporation PLC
Gemini House, Bartholomews Walk
ELY FK7 9JQ
Company Web Links
- BRIEF-Vascepa® Showed Reductions In Potentially Atherogenic Lipids And Inflammatory Markers In Patients
- BRIEF-Amarin Reports Fourth Quarter Loss Of $0.08 Per Share
- BRIEF-Amarin Prices Public Offering Of American Depositary Shares
- BRIEF-Amarin Announces Proposed Public Offering Of American Depositary Shares
- BRIEF-Amarin Announces Commencement Of Vascepa Clinical Development In Mainland China